Autism Spectrum Disorder
Conditions
Keywords
Autism Spectrum Disorder, Tryptophan metabolism, Gut microbiota
Brief summary
Autism Spectrum Disorder refers to complex neuro-developmental disorders that affect social communication and behavioral adaptation. Currently, the diagnosis of Autism Spectrum Disorder is based on a clinical examination that is performed classically during the first three years of life. The heterogeneity of the disorders occurring in autism make pathologies difficult to diagnose and manage. The overall goal of this project is the identification of metabolic biomarkers based on clinical profile. The best characterization of physiopathological pathways will ultimately allow the identification of subgroups of subjects and facilitate the development of targeted therapeutics. The proposed work aims to test the hypothesis of a disruption of tryptophan metabolism in Autism Spectrum Disorder via the gut microbiota.
Detailed description
Autism Spectrum Disorder refers to complex neuro-developmental disorders that affect social communication and behavioral adaptation. In France, Autism Spectrum Disorderaffects about 1 in 100 people according to international criteria and is diagnosed in early childhood. Currently, the diagnosis of Autism Spectrum Disorder is based on a clinical examination that is performed classically during the first three years of life. The heterogeneity of the disorders occurring in autism make pathologies difficult to diagnose and manage. The overall goal of this project is the identification of metabolic biomarkers based on clinical profile (based on behavioral and cognitive markers). The best characterization of physiopathological pathways (from the molecular scale to the phenotypic scale) will ultimately allow the identification of subgroups of subjects and facilitate the development of targeted therapeutics. The proposed work aims to test the hypothesis of a disruption of tryptophan metabolism in Autism Spectrum Disorder via the gut microbiota.
Interventions
OTHERSamples
Urinary and faecal samples
Sponsors
University Hospital, Tours
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
3 Years to 12 Years
Healthy volunteers
Yes
Inclusion criteria
(patient): * 3-12 year old child * Diagnosis of Autism Spectrum Disorders according to the DSM-5 (2013), invasive developmental disorder according to the ICD-10 (1993) or Autism Spectrum Disorders according to ICD-11 (2018) * Affiliate or beneficiary of a social security scheme * Consent signed by at least one of the parents
Exclusion criteria
(patient): * Chronic inflammatory pathology * Probiotic intake * Taking medication (except melatonin) within 6 days before inclusion and until biological samples are collected Inclusion Criteria (healthy volunteer): * 3-12 year old child * Affiliate or beneficiary of a social security scheme * Consent signed by both parents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary concentrations of tryptophan metabolites | At baseline | Quantification by High-Performance Liquid Chromatography and Mass Spectrometry |
| Faecal concentrations of tryptophan metabolites | At baseline | Quantification by using High-Performance Liquid Chromatography and Mass Spectrometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of gut microbiota | At baseline | Characterization by 16S ribosomal RNA sequencing |
| Correlation of metabolic profiles of tryptophan and microbiotic profiles | At baseline | Study of correlations from the outcomes measures 1, 2 and 3 |
Countries
France
Outcome results
None listed